crackedtooth schreef op 6 maart 2014 17:31:
CBMX micro array prenatal test, now first choice of care by ACOG and rapidly growing
Expansive growth , likely profitable this year
Low market cap
Fully financed
Late December 2013
"CombiMatrix announced earlier that the American College of Obstetricians and Gynecologists, ACOG, has issued new guidelines indicating that chromosomal microarray analysis is now recommended as the first-line genetic test in pregnancies showing fetal abnormalities on an ultrasound screen. The ACOG guidelines also indicate that microarray testing is recommended as the preferred genetic test to help identify the cause of death in stillbirths and intrauterine fetal demise when further cytogenetic analysis is desired because of its increased likelihood of obtaining results and improved detection of causative abnormalities. "
Cooperation deal with sqnm
Since late december multiple additional coverage deals:
(Fedmed national provider network, Blue Cross BLue shield Kansas, others)
12 month price target 10-20$